From their website Biogen Idec have a total of 7 drugs listed that target MS.
4 approved:
Tecfidera
Tysabri
Avonex
Famypra
3 under development:
Plegridy
Daclizumab
Anti-Lingo
Biogen have also come to the antisense party in a big way recently with 4 agreements signed with ISIS in just the last 2 years.
http://ir.isispharm.com/phoenix.zhtml?c=222170&p=irol-newsArticle&ID=1852915&highlight=
Just my opinion - 1103 offers us the clearest shot at goal.
However positive 1102 tox results will bring it back into play in a big way.
Should be a few eyes on us as Teva's MS drug Laquinimod also recently bombed. They should have stuck with 1102...
potential interest for 1102?
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $94.66M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 9.8¢ | $58.09K | 574.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 38503 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 194063 | 5 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |